Hexagon Bio uses a unique data-driven approach to discover small molecule drugs and antibody drug conjugates (ADCs) to treat cancer. They combine techniques from data science, genomics, and synthetic biology to identify therapeutics directly from DNA sequences. They focus on mining fungal genomes for inspiration, looking for new ways to target diseases with unmet medical needs.

Hexagon Bio

Scientist II / Senior Scientist, Protein Science: Antibody / ADC Analytics and Engineering

Scientist I/II, Cell Biology 

Scientist I/II, Protein Science 

Scientist II / Senior Scientist - Drug Mechanism of Action (MOA)

Senior Software Engineer

Computational Biologist / Data Scientist

Peninsula biopharma scores $77M to match natural molecules with 'undruggable' targets - The Business Journals

Hexagon Bio to Move into Clinic with $47 Million in Series A Financing - BioSpace

 Hexagon Bio Raises $61M in Private Financing Round 

Hexagon Bio raises $77.3M in Series B round, names new CSO - MM+M Online

 The Week’s 10 Biggest Funding Rounds: Dreamscape and SandboxAQ See Monster Raises 

Hexagon Bio gets $47 million to mine fungus genomes for new drugs - Chemical & Engineering News

 Venture Capital Database 2020 Now Available! 

Hexagon Bio Raises $61 Million to Advance Novel Small-Molecule Medicines Mined from Microbial Genomes - Business Wire

We’re thrilled to announce the appointment of industry leader Yujiro Hata to Hexagon Bio’s Board of Directors! An entrepreneur with over 25 years of experience building companies that have advanced innovative therapies, Yujiro currently serves as President and CEO of IDEAYA Biosciences.

We look forward to Yujiro’s strategic insights and contributions as we advance our pipeline of novel antibody-drug conjugates (ADCs) leveraging next-generation natural product-based payloads to address significant unmet needs in cancer.

Read press release: https://bit.ly/3V99rja 

#cancer #oncology #cancermedicines #antibodydrugconjugates #ADCs #metagenome #genome 


Fungi funding: Hexagon Bio snags $61M to test drugs from ...

Busy Bees: Hexagon Bio Combs Nature’s DNA to Unlock Next-Gen Medicines - Genetic Engineering and Biotechnology News

 This Biotech Startup Just Raised $47 Million To Make Drugs From Fungi 

We’re excited to announce the appointment of Kunal Patel as Senior Vice President of Business Development. Welcome, Kunal! 

Hexagon Bio Raises a $47 Million Series A to Develop Fungi-Based Medicine - Green Queen Media

Feb. 13 Quick Takes: Hexagon raises $77M for small molecules based on microbial metabolites - biocentury.com

We’re excited to welcome Yujiro Hata, President & CEO of IDEAYA Biosciences, to Hexagon Bio’s Board as we advance our pipeline of novel ADCs toward the clinic!

Leveraging our discovery platform, which integrates machine learning, genomics, chemistry, and synthetic biology to mine the global metagenome, we have identified a broad spectrum of next-generation natural product-based cytotoxic payloads for antibody-drug conjugates (ADCs). These innovations are driving our pipeline of ADC programs to address significant unmet needs in solid tumors and hematologic malignancies.

Read press release: https://bit.ly/3V99rja

#cancer #oncology #cancermedicines #antibodydrugconjugates #ADCs #metagenome #genome 

 Hexagon Bio raises $61M to continue efforts to turn fungi into drugs 

Hexagon Bio Closes $47M Series A Financing - FinSMEs

 Hexagon Bio to Move into Clinic with $47 Million in Series A Financing 

Sweet six team at Hexagon using $61M honey pot to comb microbial genomes for small-molecule drugs - BioWorld MedTech

 Hexagon Bio Raises $77.3 Million Series B Financing and Strengthens Leadership to Expand Novel Computational Discovery Platform and Advance Microbial Genome-Derived Small Molecules 

Using AI to sequence fungi genomes for cancer treatments, Hexagon Bio nets $47M in Series A - Endpoints News

Fungi funding: Hexagon Bio snags $61M to test drugs from fungi for cancer, infectious diseases - Fierce Biotech

 Hexagon Bio Raises $47M in Series A Round 

Resistance gene–guided genome mining reveals the roseopurpurins as inhibitors of cyclin-dependent kinases - pnas.org

 Using AI to sequence fungi genomes for cancer treatments, Hexagon Bio nets $47M in Series A 

 Hexagon Bio raises funds to advance preclinical pipeline in oncology and infectious diseases 

 Hexagon Bio Closes $77.3M Series B Financing Round 

Even during biotech down cycle, nearly two dozen Bay Area companies flock to major convention - The Business Journals

This Biotech Startup Just Raised $47 Million To Make Drugs From Fungi - Forbes

Hexagon Bio

About: